Randomised controlled trial
Discontinuation of Beta-Blocker Therapy after Myocardial Infarction
- Randomised controlled trial
- open-label
- non-inferiority
- multicentre (25 centres, South Korea)
Authors' conclusion
Among patients who received beta-blocker therapy beyond the first year after a myocardial infarction, discontinuation of beta-blocker therapy was noninferior to continuation with respect to a composite of death from any cause, recurrent myocardial infarction, or hospitalization for heart failure.
Study context
- Population
- Stable patients after MI with LVEF ≥40% and no HF, on beta-blocker therapy for ≥1 year after MI
- Participants
- 2,540 patients
- Comparison
- Beta-blocker discontinuation vs continuation
- Discontinuationn = 1,246
- Continuationn = 1,294reference
- Primary endpoint
- Composite of:
- All-cause death
- Recurrent MI
- Hospitalisation for HF
- Follow-up
- Median 3.1 years
Primary result
As reported in the abstract
median follow-up 3.1 years (IQR 2.5 to 3.5)
Hazard ratio
0.80
95% CI 0.57–1.13
P = 0.001 for non-inferiority
Events by treatment group
Discontinuation vs Continuation
HR 0.80 (95% CI 0.57–1.13); P for non-inferiority = 0.001
Safety
Serious adverse events
- Similar incidence in the two groups
Original publication
Discontinuation of Beta-Blocker Therapy after Myocardial Infarction. N Engl J Med. Published 30 March 2026. doi:10.1056/nejmoa2601005
Summarised from the published abstract; every number is checked against it